Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial

Simple item page
dc.conference.dateMAY 23-24, 2020
dc.conference.titleESMO Breast Cancer Virtual Meeting
dc.contributor.authorLlombart Cussac, A.
dc.contributor.authorPrat, A.
dc.contributor.authorPerez-Garcia, J. M.
dc.contributor.authorMateos, J.
dc.contributor.authorPascual, T.
dc.contributor.authorEscriva-De-Romani, S.
dc.contributor.authorStradella, A.
dc.contributor.authorRuiz-Borrego, M.
dc.contributor.authorBermejo De Las Heras, B.
dc.contributor.authorKeyaerts, M.
dc.contributor.authorSampayo-Cordero, M.
dc.contributor.authorMalfettone, A.
dc.contributor.authorCortes, R.
dc.contributor.authorGalvan, P.
dc.contributor.authorCortes, J.
dc.contributor.authorGebhart, G.
dc.contributor.authoraffiliation[Llombart Cussac, A.] Univ Catolica, Hosp Univ Arnau Vilanova, Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Llombart Cussac, A.] Med Sci Innovat Res MedSIR, Ridgewood, NJ USA
dc.contributor.authoraffiliation[Cortes, J.] Med Sci Innovat Res MedSIR, Ridgewood, NJ USA
dc.contributor.authoraffiliation[Llombart Cussac, A.] Med Sci Innovat Res MedSIR, Barcelona, Spain
dc.contributor.authoraffiliation[Cortes, J.] Med Sci Innovat Res MedSIR, Barcelona, Spain
dc.contributor.authoraffiliation[Prat, A.] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Pascual, T.] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Perez-Garcia, J. M.] IOB, Inst Oncol, Quir onSalud Grp, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Cortes, J.] IOB, Inst Oncol, Quir onSalud Grp, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Perez-Garcia, J. M.] IOB, Inst Oncol, Quir onSalud Grp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Cortes, J.] IOB, Inst Oncol, Quir onSalud Grp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Mateos, J.] IEC, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Escriva-De-Romani, S.] Hosp Univ Vall dHebron, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Stradella, A.] ICO Hosp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Ruiz-Borrego, M.] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Bermejo De Las Heras, B.] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Keyaerts, M.] Inst Jules Bordet, Med Oncol, Brussels, Belgium
dc.contributor.authoraffiliation[Gebhart, G.] Inst Jules Bordet, Med Oncol, Brussels, Belgium
dc.contributor.authoraffiliation[Sampayo-Cordero, M.] Med Sci Innovat Res MedSIR, Sci Dept, Ridgewood, NJ USA
dc.contributor.authoraffiliation[Malfettone, A.] Med Sci Innovat Res MedSIR, Sci Dept, Ridgewood, NJ USA
dc.contributor.authoraffiliation[Sampayo-Cordero, M.] Med Sci Innovat Res MedSIR, Sci Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Malfettone, A.] Med Sci Innovat Res MedSIR, Sci Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Cortes, R.] Med Sci Innovat Res MedSIR, Business Dev, Ridgewood, NJ USA
dc.contributor.authoraffiliation[Cortes, R.] Med Sci Innovat Res MedSIR, Business Dev, Barcelona, Spain
dc.contributor.authoraffiliation[Galvan, P.] IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
dc.contributor.authoraffiliation[Cortes, J.] Vall dHebron Inst Oncol, Barcelona, Spain
dc.date.accessioned2025-01-07T15:31:44Z
dc.date.available2025-01-07T15:31:44Z
dc.date.issued2020-05-01
dc.identifier.doi10.1016/j.annonc.2020.03.040
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420361196/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27210
dc.identifier.wosID538879300090
dc.issue.number2
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS50-S50
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titlePredictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía